文献速递肾血管病与高血压慢性肾脏病

动脉粥样硬化性肾血管疾病:KDIGO争议会议解读

Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference.
PubMed 文献 · Am J Kidney Dis · 2021-08-09

本文基于KDIGO争议会议专家共识,综述动脉粥样硬化性肾血管疾病(ARVD)的流行病学、诊断与治疗。ASTRAL和CORAL试验显示经皮肾动脉血运重建未改善主要结局,但药物治疗已进步,肾素-血管紧张素-醛固酮系统阻滞剂为高血压主要治疗手段。识别肾功能可挽救的肾动脉狭窄标准仍在演变,某些高危人群可能从血运重建中获益。

要点

  • ASTRAL和CORAL试验显示血运重建未优于最佳药物治疗。
  • RAAS阻滞剂是ARVD相关高血压的主要治疗手段。
  • 识别可挽救肾功能肾动脉狭窄的标准仍在演变。

核心结论

  • 经皮肾动脉血运重建未改善主要结局,但特定高危人群可能获益。
  • 药物治疗(包括他汀和降压药)是ARVD管理的基石。

研究设计与样本

  • 基于KDIGO争议会议专家小组共识的综述。

主要发现

  • ASTRAL(2009)和CORAL(2013)随机对照试验显示经皮肾动脉血运重建未改善主要结局。
  • 肾素-血管紧张素-醛固酮系统阻滞剂是ARVD高血压的主要治疗手段。
  • 识别肾功能可挽救的肾动脉狭窄标准仍在演变。
  • 某些高危临床表现人群可能从血运重建中获益。

关键数值与推荐

  • ASTRAL和CORAL试验随访3-5年,血运重建未优于最佳药物治疗。

临床怎么用

  • ARVD患者应优先采用最佳药物治疗,包括他汀和降压药。
  • RAAS阻滞剂可用于治疗ARVD相关高血压。
  • 对特定高危临床表现患者可考虑血运重建。

局限性

  • 许多争议问题仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The diagnosis and management of atherosclerotic renovascular disease (ARVD) is complex and controversial. Despite evidence from the ASTRAL (2009) and CORAL (2013) randomized controlled trials showing that percutaneous renal artery revascularization did not improve major outcomes compared with best medical therapy alone over 3-5 years, several areas of uncertainty remain. Medical therapy, including statin and antihypertensive medications, has evolved in recent years, and the use of renin-angiotensin-aldosterone system blockers is now considered the primary means to treat hypertension in the setting of ARVD. However, the criteria to identify kidneys with renal artery stenosis that have potentially salvageable function are evolving. There are also data suggesting that certain high-risk populations with specific clinical manifestations may benefit from revascularization. Here, we provide an overview of the epidemiology, diagnosis, and treatment of ARVD based on consensus recommendations from a panel of physician experts who attended the recent KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference on central and peripheral arterial diseases in chronic kidney disease. Most focus is provided for contentious issues, and we also outline aspects of investigation and management of ARVD that require further research.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Hicks CW, Clark TWI, Cooper CJ, et al. Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. Am J Kidney Dis. 2021. PMID: 34384806. doi:10.1053/j.ajkd.2021.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。